Foxo4-DRI vs Livagen

D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

FOXO4-DRI is a synthetic D-amino acid retro-inverso (DRI) peptide that disrupts the interaction between the FOXO4 transcription factor and p53 in senescent cells, triggering apoptosis selectively in cells with an activated senescent secretory phenotype (SASP) while sparing non-senescent cells in which this interaction is not tonically antiapoptotic. In senescent cells, overexpressed FOXO4 sequesters p53 in the nucleus and prevents it from initiating apoptosis, enabling the persistence of metabolically active senescent cells that secrete pro-inflammatory SASP cytokines; FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, freeing p53 to activate its apoptotic transcriptional program specifically in cells where the FOXO4 sequestration is functionally relevant. The foundational study published in Cell demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells in vivo in mice, restoring tissue homeostasis in both chemotherapy-induced and naturally aged animals; subsequent molecular modeling work has characterized the FOXO4-TP53 interaction interface to guide further senolytic peptide design, though published evidence in humans is absent and the preclinical literature remains limited. FOXO4-DRI is a research compound with no regulatory approval in any jurisdiction; it has been studied only in preclinical animal models, and no human pharmacokinetic, safety, or clinical efficacy data has been established.

Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways

Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin organization through proposed regulatory mechanisms analogous to other short Khavinson-class bioregulators. Like other Khavinson bioregulator peptides, livagen is proposed to modulate gene expression in target hepatocyte cells through epigenetic and transcriptional mechanisms, with tissue-specific targeting proposed to support hepatocyte function and liver regenerative capacity under conditions of aging-related cellular stress. Published research on Khavinson-class ultrashort peptides has characterized neuroepigenetic mechanisms of action in aging tissue models and demonstrated peptide regulation of cell differentiation in progenitor populations, providing the class-level mechanistic context for livagen's proposed hepatic regulatory effects. Livagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.